MGC Pharmaceuticals, Ltd.

Belkins
MGC Pharmaceuticals Ltd. is an Australian Company publicly listed on the ASX (ASX:MXC) founded in early 2015 by leading Israeli medical cannabis industry executives. The goal was establishing a global cannabinoid (CBD) and medical cannabis business utilizing their intellectual property, expertise and contacts, with a focus on the CBD market in Europe and Australia. MGC is operates globally with an agenda of adding value to the whole product chain, from growing and breeding unique strains to developing medicine delivery systems. With the Medical Cannabis industry, and particularly the CBD subsection of this industry booming globally, now is a time where making correct choices in partnerships and associations becomes most crucial.

Related News

WEBINAR HOSTED BY XTALKS TO COVER ACTIONS PHARMACEUTICAL COMMERCIAL TEAMS CAN TAKE TO STAY ON TRACK WITH 2020 GOALS

Xtalks | July 08, 2020

news image

COVID-19 swiftly changed the healthcare landscape around the world. There has been no rulebook for pharmaceutical commercialization during COVID-19. Pharmaceutical commercialization teams have had to quickly adapt to meet customer, community and business needs. Remote customer engagement and increased patient support services were the answer in the short term for pharmaceutical commercialization amid COVID-19. Longer term, teams will need to adapt brand strategy and executional approaches for in...

Read More

ASTELLAS, CYTOMX FORM T-CELL ENGAGING CANCER ANTIBODIES PARTNERSHIP

PharmaTimes | March 26, 2020

news image

Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer. The companies have revealed that the deal, which is potentially worth more than $1.6 billion, will focus on several initial programmes, with CytomX leading research and discovery activities, up to clinical candidate selection, which will be funded by Astellas. As part of the deal, Astellas has c...

Read More

COVID-19 ANTI-VIRAL DRUG REMDESIVIR EFFECTIVE ON MONKEYS AND PEOPLE

AsiaNews | April 18, 2020

news image

Washington (AsiaNews/Agencies) – The anti-viral drug remdesivir has proven effective in treating monkeys and people with COVID-19. Trial results have not yet been fully vetted by the scientific community, but they present good prospects for coronavirus patients. In a US study published yesterday by the National Institute of Infectious Diseases, two groups of six macaques were infected with the SARS-CoV-2, the coronavirus that causes COVID-19. One was treated with the antiviral drug remdesi...

Read More

PHARMA TECH

FUSION PHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL DATA SUPPORTING ITS FPI-1966 AND FPI-2059 TARGETED ALPHA THERAPIES

Fusion | October 23, 2021

news image

Fusion Pharmaceuticals a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine target...

Read More
news image

WEBINAR HOSTED BY XTALKS TO COVER ACTIONS PHARMACEUTICAL COMMERCIAL TEAMS CAN TAKE TO STAY ON TRACK WITH 2020 GOALS

Xtalks | July 08, 2020

COVID-19 swiftly changed the healthcare landscape around the world. There has been no rulebook for pharmaceutical commercialization during COVID-19. Pharmaceutical commercialization teams have had to quickly adapt to meet customer, community and business needs. Remote customer engagement and increased patient support services were the answer in the short term for pharmaceutical commercialization amid COVID-19. Longer term, teams will need to adapt brand strategy and executional approaches for in...

Read More
news image

ASTELLAS, CYTOMX FORM T-CELL ENGAGING CANCER ANTIBODIES PARTNERSHIP

PharmaTimes | March 26, 2020

Astellas has entered into a new partnership with CytomX Therapeutics, in order to develop T-cell engaging bispecific antibodies targeting CD3 and tumour cell surface antigens for the treatment of cancer. The companies have revealed that the deal, which is potentially worth more than $1.6 billion, will focus on several initial programmes, with CytomX leading research and discovery activities, up to clinical candidate selection, which will be funded by Astellas. As part of the deal, Astellas has c...

Read More
news image

COVID-19 ANTI-VIRAL DRUG REMDESIVIR EFFECTIVE ON MONKEYS AND PEOPLE

AsiaNews | April 18, 2020

Washington (AsiaNews/Agencies) – The anti-viral drug remdesivir has proven effective in treating monkeys and people with COVID-19. Trial results have not yet been fully vetted by the scientific community, but they present good prospects for coronavirus patients. In a US study published yesterday by the National Institute of Infectious Diseases, two groups of six macaques were infected with the SARS-CoV-2, the coronavirus that causes COVID-19. One was treated with the antiviral drug remdesi...

Read More
news image

PHARMA TECH

FUSION PHARMACEUTICALS ANNOUNCES PRESENTATION OF PRECLINICAL DATA SUPPORTING ITS FPI-1966 AND FPI-2059 TARGETED ALPHA THERAPIES

Fusion | October 23, 2021

Fusion Pharmaceuticals a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data that provide further support of its FPI-1966 and FPI-2059 targeted alpha therapies at the 34th Annual European Association of Nuclear Medicine Congress. These data reinforce the clinical dosing regimen of FPI-1966 and highlight the potential of FPI-2059 as an actinium-225 labelled precision medicine target...

Read More

Resources

resource image

PHARMACY MARKET

A pharma outsourcing mission

Article

resource image

BUSINESS INSIGHTS

2021 global life sciences outlook

infographic

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us